Candriam Luxembourg S.C.A. raised its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 12.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 293,000 shares of the biopharmaceutical company’s stock after buying an additional 33,000 shares during the period. Candriam Luxembourg S.C.A. owned approximately 0.28% of Lexicon Pharmaceuticals worth $4,820,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in LXRX. Norges Bank acquired a new position in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $12,582,000. Teachers Advisors LLC increased its position in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock valued at $1,478,000 after buying an additional 27,378 shares during the period. Macquarie Group Ltd. increased its position in Lexicon Pharmaceuticals by 22.4% in the fourth quarter. Macquarie Group Ltd. now owns 68,431 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 12,531 shares during the period. Boston Advisors LLC increased its position in Lexicon Pharmaceuticals by 9.0% in the first quarter. Boston Advisors LLC now owns 32,655 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 2,695 shares during the period. Finally, Old Mutual Global Investors UK Ltd. increased its position in Lexicon Pharmaceuticals by 38.2% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 421,242 shares of the biopharmaceutical company’s stock valued at $6,040,000 after buying an additional 116,513 shares during the period.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12. The business had revenue of $12 million during the quarter, compared to analyst estimates of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company’s quarterly revenue was down 40.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.37) EPS.
ILLEGAL ACTIVITY NOTICE: “Candriam Luxembourg S.C.A. Increases Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/07/candriam-luxembourg-s-c-a-increases-position-in-lexicon-pharmaceuticals-inc-nasdaqlxrx.html.
Several equities analysts recently commented on LXRX shares. HC Wainwright set a $27.00 price target on shares of Lexicon Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 3rd. BidaskClub raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 14th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $26.80.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
